AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02815215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Carroll's Technique
Description: Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
Study NCT02815215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ponseti method
Description: As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
Study NCT03386084 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: microwave diathermy
Description: Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
Study NCT03386084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave diathermy
Description: Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
Study NCT01865292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
Study NCT01865292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
Study NCT02585557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Support
Description: The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
Study NCT02440750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: operative hysteroscopy
Description: Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
Study NCT02440750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: 21 days administration of dienogest 2 mg/die
Study NCT02440750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Description: 21 days administration of ulipristal acetate 5 mg/die
Study NCT02589977 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
Study NCT01106924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: daily probiotic consumption
Study NCT04652089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Description: Simvastatin 20mg once a day for 7 days
Study NCT04652089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 7 days
Study NCT01136954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
Study NCT03478280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brodalumab
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Study NCT03478280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Study NCT04013464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10-20mg/d
Study NCT02661724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCBR-Pain
Description: The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
Study NCT04129541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same Day Discharge
Description: Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
Study NCT04129541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overnight Hospitalization
Description: Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
Study NCT01106924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo consumption
Study NCT01025635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Description: Applied topically twice daily for 12 weeks
Study NCT01025635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Applied topically twice daily for 12 weeks
Study NCT00663247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 3 grams daily for 3 months
Study NCT00663247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 grams daily for 3 months
Study NCT00459056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR + Lisinopril
Description: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
Study NCT00459056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol CR + Lisinopril
Description: Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
Study NCT02553837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hantavax injection
Description: A single 0.5mL dose intramuscular or subcutaneous injection
Study NCT03406533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.
Study NCT03406533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
Study NCT03406533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Study NCT03552744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed training intervention
Description: PCPs from the intervention group will be mailed an intervention package that includes:~1. 2-page structured evidence summary on CRC screening and information about Colonoscopy \& FIT (Decision box)~2. patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~3. video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4. 4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~5. individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~6. 2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~7. sample FIT for PCPs who may not be familiar with its contents and use
Study NCT03514420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKCEA-ANGPTL3-LRx
Description: AKCEA-ANGPTL3-LRx solution for SC injection.
Study NCT00459056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril + HCTZ
Description: Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
Study NCT03406533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Study NCT03406533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Study NCT03545282 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Amigas Latinas Motivando el Alma (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions.
Study NCT00459056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril + HCTZ
Description: Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
Study NCT03233880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1gm
Description: Azithromicin 1 gm oral single dose
Study NCT03233880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo
Study NCT03216928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Study NCT05513118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal clinical examination and gingival crevicular fluid, saliva, dental plaque, serum sampling
Description: Probing pocket depth was defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) was measured as distance from cementoenamel junction to the base of pocket and recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva was obtained by each participant. Subgingival dental plaque was collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Gingival crevicular fluid samples were collected with absorbent paper strips. Serum samples were also collected at the time of visit.
Study NCT01802853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: Single subcutaneous dose
Study NCT01802853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO6811135
Description: Single intravenous dose
Study NCT04082858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
Study NCT04082858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
Study NCT04278391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1421
Description: 1 tablet administered in fasting condition
Study NCT04278391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC201903
Description: 1 tablet administered in fasting condition
Study NCT01644058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading
Study NCT02350621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Study NCT03545282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amigas Latinas Motivando el Alma (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions.
Study NCT02350621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimal invasive Posterior Cervical Foraminotomy
Study NCT01963728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Isophane
Description: daily dosing based on fasting morning glucose levels
Study NCT01963728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: daily dose based on fasting morning glucose levels
Study NCT00961168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume Control Ventilation
Description: Mechanical ventilation at a constant tidal volume of 6 mL/kg.
Study NCT00961168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation
Description: Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
Study NCT01616381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: PDE-5 Inhibitor
Study NCT01616381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for sildenafil 40mg x 3 daily
Study NCT01808794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mucograft
Description: Mucograft Collagen Matrix
Study NCT01808794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamatrix
Description: Dynamatrix
Study NCT04138979 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide
Description: First use of chemotherapy after breast cancer
Study NCT02386683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lung-protective ventilation
Description: mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
Study NCT02890615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression self-care
Description: Toolkit and coaching
Study NCT02535780 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS
Study NCT02535780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: TMS
Study NCT02535780 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS
Study NCT02535780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS
Study NCT03320525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T-ChOS
Description: T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
Study NCT01247805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Single oral dose of 1 x 20 mg IR oral tablet.
Study NCT01247805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
Study NCT01247805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
Study NCT00248560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
Study NCT00248560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
Study NCT01762579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat flour
Description: wheat flour is administered three times per day for 15 days
Study NCT01762579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat flour
Description: wheat flour is administered three times per day for 15 days
Study NCT02628925 — intervention group
Intervention type: DEVICE
Intervention: Nu-DESC DK
Description: Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
Study NCT02726399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
Study NCT02726399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
Study NCT02726399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80mg/m2 administered as an IV infusion every 21 days
Study NCT00635713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 125mg
Study NCT00635713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: ARIMIDEX
Study NCT01762579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Xylose
Description: Xylose will be administered three times per day for 15 days
Study NCT00635713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250mg
Study NCT02131883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-Cognitive Behavioral Therapy
Description: psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
Study NCT02131883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List with treatment as usual
Description: Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
Study NCT02139319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Study NCT02139319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01339169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
Study NCT01659905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Chewable Tablet
Study NCT01762579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylose
Description: Xylose will be administered three times per day for 15 days
Study NCT03568838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
Study NCT01238120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 200 mg BID and 8 hours apart
Study NCT01238120 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
Study NCT01238120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg BID and 8 hours apart